- RecruitingPHASE3
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
This study compares a new treatment called IMA203 with standard care for advanced skin melanoma that has already been treated. Its main goal is to see if IMA203 is more effective and safe for patients who have limited treatment options.
For: Melanoma, Cutaneous MalignantUnited States · Canada · France - Active not recruitingPHASE2, PHASE3
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
This study looks at new treatments for advanced eye melanoma that has spread. It compares a combination of two drugs (IDE196 and crizotinib) with standard treatments to see which works best and is safest for patients.
For: Metastatic Uveal MelanomaUnited States · Australia · Belgium - Active not recruitingPHASE3
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
This study compares a new treatment, Volrustomig combined with standard chemotherapy, against existing treatments for advanced mesothelioma. It aims to see if the new combination is safer and more effective for patients whose cancer can't be removed by surgery.
For: Unresectable Pleural MesotheliomaUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
This study is testing two new drugs, nivolumab and ipilimumab, together for advanced liver cancer (hepatocellular carcinoma). It compares this combination to standard treatments (sorafenib or lenvatinib) to see if it helps people live longer. Participants haven't had prior treatment.
For: Hepatocellular CarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
This study looks at new drug combinations for advanced bowel cancer that has spread. It compares nivolumab alone, nivolumab with ipilimumab, and standard chemotherapy to see which works best for patients whose cancer has specific features (dMMR/MSI-H).
For: Metastatic Colorectal CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
This study looks at new treatments (nivolumab, sometimes with ipilimumab, or nivolumab with chemotherapy) for people with a certain type of lung cancer before surgery. It aims to see if these treatments are safe and how well they work to fight the cancer earlier.
For: Non-Small Cell Lung CancerUnited States · Canada - RecruitingPHASE3
The Sagittarius Trial
This study looks at new ways to treat colon cancer after surgery to stop it coming back. It uses advanced tests called 'liquid biopsies' to help doctors choose the best treatment for each person, aiming for better results and fewer side effects.
For: Colon Cancer Stage II · Colon Cancer Stage IIIGermany · Italy · Spain - RecruitingPHASE2, PHASE3
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
This study compares two drug combinations for advanced uveal melanoma. It looks at RP2 with nivolumab versus nivolumab with ipilimumab, for patients who haven't had these immune-boosting treatments before, to see which works better and is safer.
For: Metastatic Uveal MelanomaUnited States · Australia · United Kingdom - RecruitingPHASE1
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
This study is testing a new drug, zanzalintinib, alone and with other medicines, for people with advanced cancers like kidney, prostate, and lung cancer. It's looking at safety and if the treatment shrinks tumours.
For: Renal Cell Carcinoma (RCC) · Metastatic Castration-Resistant Prostate Cancer (mCRPC) · Urothelial Carcinoma (UC)United States · Australia · Austria - RecruitingPHASE1, PHASE2
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
This study looks at a new drug, mRNA-4359, by itself and with other cancer drugs. It aims to see if it's safe and what side effects it might have in people with advanced solid tumours, which are cancers that have spread.
For: Advanced Solid TumorsUnited States · Australia · Germany - RecruitingPHASE1, PHASE2
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
This study is looking at a new medicine called Pumitamig, by itself or with another medicine called Ipilimumab. It's for people in the UK with advanced liver cancer that can't be removed by surgery. The main goal is to see how safe and well these treatments are tolerated.
For: Hepatocellular Carcinoma (HCC)United States · Australia · Chile - Active not recruitingPHASE3
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
This study is testing new combinations of medicines (Nivolumab with Cabozantinib) against a standard treatment (Sunitinib) for kidney cancer that has spread. We want to see if the new combination is safer and works better for people who haven't had treatment before.
For: Renal Cell CarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
This study is looking at new ways to treat advanced kidney cancer that hasn't been treated before. It combines three medicines to see if they work better together than two, aiming to help people live longer and keep their cancer from growing.
For: Renal Cell CarcinomaUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
This study is looking at an experimental drug called Pumitamig, by itself or with other treatments, for people with advanced kidney cancer (renal cell carcinoma). Researchers want to see how safe and effective these treatments are.
For: Advanced Renal Cell Carcinoma (RCC)United States · Argentina · Australia - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
For: CancerUnited States · Argentina · Australia - Active not recruitingPHASE1
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
This study tests new ways to treat advanced pancreatic cancer. It combines a targeted drug (anetumab ravtansine) with immune-boosting medicines (nivolumab, ipilimumab) and standard chemotherapy (gemcitabine) to see if these combinations are safe and effective.
For: Pancreatic Adenocarcinoma · Stage II Pancreatic Cancer AJCC v8 · Stage III Pancreatic Cancer AJCC v8United States · Canada - Active not recruitingPHASE2
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
This study looks at treating advanced soft tissue sarcoma with a combination of two immunotherapy drugs (ipilimumab and nivolumab), alone or with an additional drug called cabozantinib, to see which works best.
For: Locally Advanced Extraskeletal Myxoid Chondrosarcoma · Locally Advanced Leiomyosarcoma · Locally Advanced LiposarcomaUnited States · Canada - Active not recruitingPHASE1, PHASE2
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
This study is testing a new cell therapy called gavo-cel for advanced cancers like mesothelioma and ovarian cancer. It explores how well gavo-cel works, both alone and with other cancer drugs, in people whose tumours produce a specific protein called mesothelin.
For: Mesothelioma · Mesothelioma, Malignant · Mesothelioma; PleuraUnited States · Canada - RecruitingPHASE1
Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma
This study is looking at a new way to treat advanced liver cancer that can't be removed with surgery. It combines two existing cancer drugs, ipilimumab and nivolumab. Doctors want to find the safest and most effective dose when ipilimumab is given directly into the liver and nivolumab is given into the bloodstream.
For: Hepatocellular CarcinomaFrance